Search clinical trials for: NVP-2203-R1 Placebo

Total 232 results

NVP Healthcare

Recruiting

To Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients

Cardiovascular Diseases

Korea, Republic of
NVP Healthcare

Completed

Pharmacokinetic Interaction and Safety Between NVP-1203-R1 and NVP-1203-R2 (Navipharm)

Healthy

Korea, Republic of
NVP Healthcare

Completed

Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1805-R1 and NVP-1805-R2

Healthy

Korea, Republic of
NVP Healthcare

Completed

Efficacy and Safety of NVP-1203 and NVP-1203-R in Patients With Acute Low Back Pain

Acute Low Back Pain

Korea, Republic of
NVP Healthcare

Completed

Efficacy and Safety of NVP-1203 in Patients With Acute Low Back Pain

Acute Low Back Pain

Korea, Republic of
NVP Healthcare

Completed

To Evaluate the Safety and the Pharmacokinetics of NVP-2203

Healthy Volunteers

Korea, Republic of
NVP Healthcare

Completed

Pharmacokinetic Characteristics and Safety After Administration of NVP-2002

Healthy

Korea, Republic of
NVP Healthcare

Completed

NVP-1805 Compared to Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Adult Volunteers (BE)

Healthy Volunteers

Korea, Republic of
NVP Healthcare

Completed

A Study to Evaluate the Food Effect on the Pharmacokinetics of NVP-1203 (NVP-1203)

Healthy

Korea, Republic of
Dong-A ST Co., Ltd.

Recruiting

Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients

Hepatitis B

Korea, Republic of
Novo Nordisk A/S

Completed

First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.

Diabetes Mellitus, Type 2

United States
Qurient Co., Ltd.

Completed

A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers

Healthy Volunteers

United States
Qurient Co., Ltd.

Completed

A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of Q203 in Normal Healthy Male and Female Volunteers

Healthy Volunteers

United States
Promentis Pharmaceuticals, Inc.

Completed

Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023

Healthy Volunteers

United States
Catabasis Pharmaceuticals

Completed

A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003

Dyslipidemia

United States
Global Alliance for TB Drug Development

Completed

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

Tuberculosis | Tuberculosis, Pulmonary

United States
Promentis Pharmaceuticals, Inc.

Completed

A Study in Patients With Trichotillomania (TTM)

Trichotillomania

United States
Catabasis Pharmaceuticals

Completed

Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia

Hypertriglyceridemia | Hyperlipoproteinemia Type I | Lipoprotein Lipase Deficiency, Familial | Chylomicronemia, Familial

Canada
Catabasis Pharmaceuticals

Completed

Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia

Metabolic Diseases | Dyslipidemias | Lipid Metabolism Disorders | Hyperlipidemias | Hypertriglyceridemia

United States
Celgene

Completed

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

Healthy

United States
Celgene

Completed

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Belgium, Germany, Spain, Canada, Serbia, Colombia, Poland, Argentina, Brazil, Mexico, Hungary, France, Russian Federation, Italy
Amgen

Completed

Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia

End Stage Renal Disease | Chronic Kidney Disease | Kidney Disease | Hyperphosphatemic
4SC AG

Completed

Single Dose Study With 4SC-203 in Healthy Volunteers

Acute Myeloid Leukemia

Germany
Alto Neuroscience

Recruiting

PD, PK, and Safety of ALTO-203 in Patients With MDD

Anhedonia | Major Depressive Disorder

United States
Celgene

Completed

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

Systemic Lupus Erythematosus

United States
Global Alliance for TB Drug Development

Completed

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary

United States
Promentis Pharmaceuticals, Inc.
Celerion

Completed

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers

Healthy

United States
Medical College of Wisconsin
National Institute on Aging (NIA)

Completed

Network-Level Mechanisms for Preclinical Alzheimer's Disease Development

APOE 4

United States
Vaccinex Inc.
PRA Health Sciences

Completed

Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS

Multiple Sclerosis

United States
Ferrer Internacional S.A.

Not yet recruiting

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy
ICM Co. Ltd.

Enrolling by invitation

A Long Term Follow-up Study of Subjects Who Received ICM-203 or Matching Placebo

Osteoarthritis, Knee

Australia
Celgene Corporation

Completed

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

Healthy Volunteers

United States
JW Pharmaceutical

Recruiting

To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Korea, Republic of
Celgene

Withdrawn

A Phase 2 Study With CC-220 in Skin Sarcoidosis

Sarcoidosis
Vaccinex Inc.
Huntington Study Group

Completed

A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi (SIGNAL-HD)

Huntington's Disease

United States, Canada
Promentis Pharmaceuticals, Inc.
Baylor College of Medicine; Celerion

Completed

Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal

Impulse Control Disorders

United States
National Institute on Drug Abuse (NIDA)
Technical Resources International, Inc.; Promentis Pharmaceuticals, Inc.; Altasciences...

Not yet recruiting

SXC-2023 Cocaine Interaction Study

Cocaine Use Disorder

United States
AVIR Green Hills Biotechnology AG
Medical University of Vienna

Completed

Dose-escalation Study of Single Dose GHB04L1 in Healthy Adults (GHB-CS03)

Influenza

Austria
AgeneBio
National Institute on Aging (NIA)

Completed

Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease (HOPE4MCI)

Mild Cognitive Impairment | Prodromal Alzheimer's Disease

United States, Canada
Shin Poong Pharmaceutical Co. Ltd.

Completed

Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA (SP-8203-2002)

Ischemic Stroke

Korea, Republic of
CSPC-NBP Pharmaceutical Co., Ltd.

Completed

NBP in Adult Patients With Acute Ischemic Stroke (AIS)

AIS

United States
FORUM Pharmaceuticals Inc
Parexel

Completed

Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

Mild Cognitive Impairment | Alzheimer's Disease

United States
Guangzhou Lupeng Pharmaceutical Company LTD.

Completed

A Study of LP-168 in Healthy Volunteers

Multiple Sclerosis | NMO Spectrum Disorder

China
Shin Poong Pharmaceutical Co. Ltd.

Completed

Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPA (SP-8203-2001)

Ischemic Stroke

Korea, Republic of
Vyluma, Inc.
Syneos Health

Active, not recruiting

CHAMP: Study of NVK-002 in Children With Myopia

Myopia

United States, Hungary, Ireland, Netherlands, Spain, United Kingdom
NervGen Pharma

Completed

A Phase I Safety Study of NVG-291 in Healthy Adults

Spinal Cord Injury

Australia
University of California, San Francisco

Completed

Davunetide (AL-108) in Predicted Tauopathies - Pilot Study

Progressive Supranuclear Palsy | Corticobasal Degeneration Syndrome | Progressive Nonfluent Aphasia | Predicted Tauopathies, Including | Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17

United States
EyebioKorea, Inc.

Completed

Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers

Healthy

Korea, Republic of
Conjupro Biotherapeutics, Inc.
CSPC-NBP Pharmaceutical Co., Ltd.

Withdrawn

NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy

Breast Cancer | Peripheral Neuropathy
ICM Biotech Australia Pty Ltd.

Recruiting

A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis

Osteoarthritis, Knee

Australia

Search clinical trials for: NVP-2203-R1 Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations